Tempus Extends Data Deal With Recursion, Licenses RNA Model Through 2029
RXRX sits 41% above its 52-week low of $2.77 on elevated volume (2.3× avg).
Summary
Tempus AI and Recursion extended their existing data license agreement through November 2029 and added a new non-exclusive worldwide license for Recursion's RNA sequencing model TxFM. The deal deepens a partnership that already produced a Genentech neuroscience target validation in August. For Recursion, this locks in a key data partner and monetizes its RNA foundation model, adding a recurring revenue stream beyond the volatile Roche/Genentech collaboration. The 8-K filed today disclosed $12M in fees for the oncology license, a modest but meaningful contribution against a $131M quarterly loss. Watch for further licensing deals as Recursion seeks to offset declining collaboration revenue.
At the time of this announcement, RXRX was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.77 to $7.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.